Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 2,073 shares at $64.03 ($133K) on 2026-10-05, disclosed to the SEC on 2026-10-07.
Scheduled sale ($133k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.03 | 1,638 | $105K | 79.0% |
| 2 | $64.16 | 435 | $28K | 21.0% |
| Total | $64.06 avg | 2,073 | $133K | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |